DBV Technologies

Report Publication Announcement • May 2, 2019

DBV Technologies to Attend Upcoming Investor Conferences

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that members of its management team will present at the following investor conferences in May 2019:

Daniel Tassé, Chief Executive Officer, and Kevin Trapp, Chief Commercial Officer, will present at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, NV, on Tuesday, May 14, 2019, at 11:20am PT.

Kevin Trapp, Chief Commercial Officer, will present at the Barclays West Coast Biopharma Conference in Calistoga, CA, on Thursday, May 30, 2019, at 10:30am PT.

A live webcast of the presentation at the Bank of America Merrill Lynch 2019 Health Care Conference will be available on the Investors & Media section of the Company's website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV's website within one hour after the event.

About DBV Technologies

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

DBV Investor Relations Contact

Sara Blum Sherman Senior Director, Investor Relations & Strategy +1 212-271-0740 sara.sherman@dbv-technologies.com

DBV Media Contact

Joe Becker VP, Global Corporate Communications +1-646-650-3912 joseph.becker@dbv-technologies.com